Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired GoodRx Holdings, Inc. (“GoodRx”) (NASDAQ: GDRX) securities between September 23, 2020 and May 10, 2021, inclusive (the “Class Period”).
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or concealing material averse facts. Specifically, the complaint alleges that GoodRx made false and misleading statement in its initial public offering (“IPO”) that created a scheme that: (1) deceived the investing public regarding GoodRx’s business, operations, services, competition, competitive market trends and present and future business prospects; (2) facilitated the company’s September 2020 IPO; (3) created artificial demand for the GoodRx common shares sold in the IPO; (4) enabled the company to receive $887 million in net proceeds from the sale of GoodRx common stock in the IPO; (5) enabled certain existing shareholders, including affiliates of the Individual Defendants, executive officers and company employees, to collectively reap gross proceeds of more than $369 million from the sale of GoodRx common stock in the IPO; and (6) caused plaintiff and the Class to purchase GoodRx publicly traded common stock at artificially inflated prices.
Current Status of Case:
On June 9, 2022, the Court granted Defendants’ Motion to Dismiss the Amended Complaint. This case has concluded.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.